Cognitive screening for lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates cognitive impairment related to cancer and its treatment in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It aims to assess the presence of cognitive deficits during the first year after enrollment using comprehensive neuropsychological assessments. The study focuses on understanding how lung cancer and its therapies may affect cognitive function over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
* Age ≥ 18 years
* Patients able to speak and read the local language(s) fluently
* Acceptance and signature of informed consent

Exclusion Criteria:

* Age ≥ 70
* Presence of brain metastases
* Patients with concomitant neurological or psychiatric disorders.
* Patients undergoing brain radiotherapy
* Previous diagnosis of lung cancer

Where it's running

• Istituto Europeo di Oncologia
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Gabriella Pravettoni — Istituto Europeo di Oncologia
• Study coordinator: Gabriella Pravettoni
• Email: gabriella.pravettoni@ieo.it
• Phone: +39025489731

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating KQB365 for treating advanced solid tumors

  This study tests if a new treatment called KQB365, alone or with another drug, can help adults with advanced solid tumors that have specific genetic mutations.

  Recruiting at 11 sites Phase 1 Kumquat Biosciences Inc. · Phoenix, Arizona and 10 other locations · NCT06720987

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

• Icotinib after surgery for early EGFR-mutant NSCLC

  This study tests whether giving icotinib after surgery helps patients with early-stage EGFR-mutant NSCLC compare to just following them after surgery.

  Recruiting at 2 sites Betta Pharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07806604

• Oral Paclitaxel with Immunotherapy and SBRT as Neoadjuvant Treatment for Older Adults with NSCLC

  This trial tests a new, lighter neoadjuvant therapy that combines an oral paclitaxel solution, an immune checkpoint inhibitor, and SBRT for adults aged 70 and older with resectable NSCLC to see if it can shrink tumors before surgery.

  Recruiting Phase 4 Shanghai Pulmonary Hospital, Shanghai, China · Guangzhou, Guangdong and 4 other locations · NCT07754812

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.